Compare Amgen, Inc. (AMGN) vs GXO Logistics Inc (GXO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs GXO Logistics Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while GXO Logistics Inc trades at $50.61 (market cap $5.82B). The key difference: Amgen, Inc. is far larger — about 33.7× GXO Logistics Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| AMGN | GXO | |
|---|---|---|
Market Cap | $196.12B | $5.82B |
Sector | Health | Industrials |
52-Week High | $388.16 | $65.59 |
52-Week Low | $271.18 | $45.52 |
Enterprise Value | $241.41B | $10.99B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GXO Logistics trades at $50.61, down 2.15% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters and holds a low P/S ratio of 0.43. Recent news highlights new partnership renewals and expansion in Europe, supporting growth prospects.
Wall Street analysts are overwhelmingly bullish with an 88.89% buy rating and a $69.33 consensus price target, implying significant upside. Key risks include competitive pressures from Amazon and reliance on retail clients, but improving profit margins and a record sales pipeline provide a positive fundamental outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
